Celtaxsys is seeking to combat disease conditions that result from over-activated neutrophils by tuning down excessive neutrophil response without turning it off completely, thereby reducing collateral tissue damage while preserving immune protection against injury and infection.
Neutrophils are the most abundant immune cells in the body. They help protect the body from injury and infection. However, over-activation of neutrophils causes extensive collateral damage to healthy tissues leading to functional impairment and scarring – a hallmark of many inflammatory diseases. As a result, the neutrophil response designed to protect the body begins to cause harm.
In many such inflammatory diseases, the neutrophil signaling pathway governed by the potent inflammation mediator Leukotriene B4 (LTB4) and the recovery mediator Lipoxin A4 (LXA4) becomes imbalanced, leading to over-activation of neutrophils with sustained inflammation and tissue damage.
(Click Image to Enlarge)
When properly balanced, LTB4 and LXA4 work together to help the body fight and recover from injury and infection.
Celtaxsys’ flagship drug candidate, once-daily oral acebilustat, is intended to re-establish the LTB4-LXA4 inflammation-recovery balance and return the neutrophil response to a healthy state (homeostasis).